A Comparison of Bone Morphogenetic Protein-7 Mutant Expression in Prokaryotic and Eukaryotic Hosts

Authors
L. Nematollahi 1
F. Mahboudi 2
M. Azizi 3
F. Barkhordari 4
A. Adeli 4
V. Khalaj 5
1 Ph.D. Candidate, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
2 Associated Professor, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
3 Ph.D., Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
4 B.Sc., Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
5 Assistant Professor, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Abstract
Objective: Bone morphogenetic protein-7 (BMP-7) is a multifunctional growth factor predominantly recognized for its osteoinductive properties. Due to the high cost of this protein, the availability of BMP-7 for treatment is limited. The heterologous production of recombinant hBMP-7 has been performed in a number of expression systems. In this study a novel form of BMP-7 was expressed in eukaryotic and prokaryotic hosts. Methods: For expression in the prokaryotic system, the novel protein was secreted to the periplasmic space of Escherichia coli using a pelB signal sequence followed by single-step purification by Ni2+-charged column chromatography. In the mammalian cell expression system, we transferred a full-length cDNA encoding precursor of the novel protein to CHO cells then selected stable clones by using the appropriate antibiotic concentration. Expressions in both systems were confirmed by Western blot analysis. Results: The novel recombinant protein was produced as a 36-38 kDa dimer in the CHO cell line and a 16 kDa monomer in the Escherichia coli system. Quantitative analysis according to ELISA showed that the expression levels of the mutant protein in the eukaryotic and prokaryotic expression systems were 40 ng/ml and 135 ng/ml of the culture media, respectively. Conclusion: In this study, the expression level in Escherichia coli was at least three times more than observed in the CHO cells. However, further optimization is required to obtain a dimer protein in Escherichia coli. The results show that periplasmic expression may be suitable for the production of complex proteins such as BMPs.

Keywords

 
 
[1]     Xiao YT, Xiang LX, Shao JZ. Bone morpho-genetic protein. Biochem Biophys Res Commun 2007; 362(3): 550-3.
[2]     Dimitriou R, Giannoudis PV. Discovery and development of BMPs. Injury 2005; 36(Suppl 3): S28-33.
[3]     Gazzerro E, Minetti C. Potential drug targets within bone morphogenetic protein signaling pathways. Curr Opin Pharmacol 2007; 7(3): 325-33.
[4]     Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007; 77(8): 626-31.
[5]     De Biase P, Capanna R. Clinical applications of BMPs. Injury 2005; 36(Suppl 3): S43-6.
[6]     Dinopoulos H, Giannoudis PV. (iv) The use of bone morphogenetic proteins (BMPs) in long-bone non-:union:s. Curr Orthopaed 2007; 21(4): 268-79.
[7]     Jeong GK, Sandhu HS, Farmer J. Bone morphogenic proteins: applications in spinal surgery. HSS J 2005; 1(1): 110-7.
[8]     Granjeiro JM, Oliveira RC, Bustos-Valenzuela JC, Sogayar MC, Taga R. Bone morphogenetic proteins: from structure to clinical use. Braz J Med Biol Res 2005; 38(10): 1463-73.
[9]     Carlisle E, Fischgrund JS. Bone morphogenetic proteins for spinal fusion. Spine J 2005; 5(Suppl 6): S240-9.
[10]  Jayapal KP, Wlaschin KF, Hu W, Yap MGS. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem Eng Prog. 2007; 103(10): 40.
[11]  Robbens J, De Coen W, Fiers W, Remaut E. Improved periplasmic production of biologically active murine interleukin-2 in Escherichia coli through a single amino acid change at the cleavage site. Process Biochem 2006; 41(6): 1343-6.
[12]  Soares CRJ, Gomide FIC, Ueda EKM, Bartolini P. Periplasmic expression of human growth hormone via plasmid vectors containing the λPL promoter: use of HPLC for product. Protein Eng 2003; 16(12): 1131-8.
[13]  Balderas Hernández VE, Paz Maldonado LM, Medina Rivero E, Barba de la Rosa AP, Jiménez-Bremont JF, Ordoñez Acevedo LG, De León Rodríguez A. Periplasmic expression and recovery of human interferon gamma in Escherichia coli. Protein Expr Purif 2008; 59(1): 169-74.
[14]  Ambrus A, Torocsik B, Adam-Vizi V. Periplasmic cold expression and one-step purification of human dihydrolipoamide dehydrogenase. Protein Expr Purif 2009; 63(1): 50-7.
[15]  Rastgar Jazii F, Karkhane AA, Yakhchali B, Fatemi SS, Deezagi A. A simplified purification procedure for recombinant human granulocyte macrophage-colony stimulating factor from periplasmic space of Escherichia coli. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856(1-2): 214-21.
[16]  Nossal NG, Heppel LA. The release of enzymes by osmotic shock from Escherichia coli in exponential phase. J Biol Chem 1966; 241(13): 3055-62.
[17]  Coligan JE, Dunn BM, Speicher DW, Wingfield PT. Short protocol in protein science: a compendium of methods from current protocols in protein science. New York: John Wiley and Sons, 2003; p: 43-7.
[18]  Calori GM, Donati D, Di Bella C, Tagliabue L. Bone morphogenetic proteins and tissue engineering: future directions. Injury 2009; 40(Suppl 3): S67-76.
[19]  Di Liddo R, Grandi C, Venturini M, Dalzoppo D, Negro A, Conconi MT, Parnigotto PP. Recombinant human TAT-OP1 to enhance NGF neurogenic potential: preliminary studies on PC12 cells. Protein Eng Des Sel 2010; 23(11): 889-97.
[20]  Swencki-Underwood B, Mills JK, Vennarini J, Boakye K, Luo J, Pomerantz S, Cunningham MR, Farrell FX, Naso MF, Amegadzie B. Expression and characterization of a human BMP-7 variant with improved biochemical properties. Protein Expr Purif 2008; 57(2): 312-9.
[21]  Israel DI, Nove J, Kerns KM, Moutsatsos IK, Kaufman RJ. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors 1992; 7(2): 139-50.
[22]  Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM, Pang RH. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992; 267(28): 20352-62.

[23] Kim CK, Oh SD, Rhee JI, Lee EM, Yoon TR Expression and purification of recombinant human bone morphogenetic protein-7 (rhBMP-7) in Bacillus subtilis. Biotechnol Bioprocess Eng 2010; 15(5): 830-6.



[24]  Chen L, Huang YD, Zhang YD. Expression and secretion of human bone morphogenetic protein-7 in Pichia pastoris. Sheng Wu Gong Cheng Xue Bao 2006; 22(6): 907-13.
[25]  Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242(4885): 1528-34.
[26]  Swartz JR. Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol 2001; 12(2): 195-201.
[27]  Kiany J, Zomorodipour A, Ahmadzadeh Raji M, Sanati MH. Construction of recombinant plasmids for periplasmic expression of human growth hormone in Escherichia coli under T7 and lac promoters. J Sci I R Iran 2003; 14(4): 311-6.
Pathobiology Reserach
Volume 15, Issue 3
October 2012
Pages 93-102